Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Alecensa alectinib: Phase II data

    Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Alecensa alectinib (CH5424802, RG7853, RO5424802, AF802) Business: Cancer Molecular target: Anaplastic …

    Published on 5/25/2015
  • Alecensa alectinib: Phase II data

    Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Alecensa alectinib (CH5424802, RG7853, RO5424802, AF802) Business: Cancer Molecular target: Anaplastic …

    Published on 5/25/2015
  • AMG 334: Phase II data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Product: AMG 334 Business: Neurology Molecular target: Calcitonin gene-related peptide (CGRP) Description: Human mAb inhibiting the receptor for calcitonin gene-related …

    Published on 5/25/2015
  • Anti-PDL1: Additional Phase Ia data

    Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Anti-PDL1 (MPDL3280A, RG7446) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (…

    Published on 5/25/2015
  • Anti-PDL1: Interim Phase II data

    Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Anti-PDL1 (MPDL3280A, RG7446) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (…

    Published on 5/25/2015
  • Anti-PDL1: Phase Ib data

    Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Anti-PDL1 (MPDL3280A, RG7446) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (…

    Published on 5/25/2015
  • Avastin bevacizumab: Phase III data

    Genentech Inc., South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Avastin bevacizumab (RG435) Business: Cancer Molecular …

    Published on 5/25/2015
  • Avelumab: Phase Ib data

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Avelumab (MSB0010718C) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: …

    Published on 5/25/2015
  • CAR-T CD30: Phase I data

    Cellular Biomedicine Group Inc. (NASDAQ:CBMG), Palo Alto, Calif. Product: CAR-T CD30 Business: Cancer Molecular target: CD30 Description: T cells expressing a chimeric antigen receptor (CAR) specific to the CD30 antigen…

    Published on 5/25/2015
  • Carfilzomib: Additional Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Product: Carfilzomib (Kyprolis) (PR-171, ONO-7057) Business: Cancer Molecular target: Proteasome Description: …

    Published on 5/25/2015
  • Carfilzomib: Phase I/II data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Product: Carfilzomib (Kyprolis) (PR-171, ONO-7057) Business: Cancer Molecular target: Proteasome Description: …

    Published on 5/25/2015
  • CB-839: Preliminary Phase I data

    Calithera Biosciences Inc. (NASDAQ:CALA), South San Francisco, Calif. Product: CB-839 Business: Cancer Molecular target: Glutaminase (GLS) Description: Oral selective glutaminase (GLS) inhibitor Indication: Treat …

    Published on 5/25/2015
  • CVac: Phase II final data

    Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD), Sydney, Australia Product: CVac Business: Cancer Molecular target: Mucin 1 (MUC1) (CD227) Description: Ex vivo cancer vaccine using a patients own dendritic cells primed with …

    Published on 5/25/2015
  • EBI-005: Phase III data

    Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Product: EBI-005 Business: Ophthalmic Molecular target: Interleukin-1 (IL-1) Description: IL-1 receptor antagonist Indication: Treat dry eye disease Endpoint: …

    Published on 5/25/2015
  • Elotuzumab: Interim Phase III data

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Elotuzumab (HuLuc63, BMS-901608) (formerly PDL 063) Business: Cancer Molecular target: Cell-surface glycoprotein CS1 …

    Published on 5/25/2015
  • GEN-003: Phase II data

    Genocea Biosciences Inc. (NASDAQ:GNCA), Cambridge, Mass. Novavax Inc. (NASDAQ:NVAX), Gaithersburg, Md. Product: GEN-003 Business: Infectious Molecular target: Infected cell polypeptide 4 (ICP4) Description: T cell …

    Published on 5/25/2015
  • IV ALD403: Additional Phase Ib data

    Alder Biopharmaceuticals Inc. (NASDAQ:ALDR), Bothell, Wash. Product: IV ALD403 Business: Neurology Molecular target: Calcitonin gene-related peptide (CGRP) Description: mAb targeting calcitonin gene-related peptide (…

    Published on 5/25/2015
  • Keytruda pembrolizumab: Additional Phase Ib data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Keytruda pembrolizumab (MK-3475) (formerly lambrolizumab) Business: Cancer Molecular target: Programmed cell death 1 (PD-1) (PDCD1) (CD279) Description: …

    Published on 5/25/2015
  • Keytruda pembrolizumab: Interim Phase I/II data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Keytruda pembrolizumab (MK-3475) (formerly lambrolizumab) Business: Cancer Molecular target: Programmed cell death 1 (PD-1) (PDCD1) (CD279) Description: …

    Published on 5/25/2015
  • Keytruda pembrolizumab: Preliminary Phase Ib data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Keytruda pembrolizumab (MK-3475) (formerly lambrolizumab) Business: Cancer Molecular target: Programmed cell death 1 (PD-1) (PDCD1) (CD279) Description: …

    Published on 5/25/2015
  • Keytruda pembrolizumab: Preliminary Phase I/II data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Keytruda pembrolizumab (MK-3475) (formerly lambrolizumab) Business: Cancer Molecular target: Programmed cell death 1 (PD-1) (PDCD1) (CD279) Description: …

    Published on 5/25/2015
  • LentiGlobin BB305 gene therapy: Additional Phase I/II data

    bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Product: LentiGlobin BB305 gene therapy Business: Hematology Molecular target: NA Description: Autologous CD34+ stem cells transduced ex vivo with a lentiviral vector …

    Published on 5/25/2015
  • MEDI4736: Additional Phase I data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: MEDI4736 Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: Human IgG1 mAb targeting programmed cell death…

    Published on 5/25/2015
  • MEDI4736: Additional Phase Ib data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: MEDI4736 Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: Human IgG1 mAb targeting programmed cell death…

    Published on 5/25/2015
  • MEDI4736: Interim Phase I data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: MEDI4736 Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: Human IgG1 mAb targeting programmed cell death…

    Published on 5/25/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993